Market Overview - The medical services sector experienced a decline of 1.41% on January 26, with Meidisi leading the drop [1] - The Shanghai Composite Index closed at 4132.61, down 0.09%, while the Shenzhen Component Index closed at 14316.64, down 0.85% [1] Stock Performance - Notable gainers in the medical services sector included: - Guangzheng Eye Hospital (002524) with a closing price of 5.05, up 10.02% on a trading volume of 266,400 shares and a transaction value of 132 million [1] - Lanwei Medical (301060) closed at 12.28, up 3.98% with a trading volume of 325,000 shares and a transaction value of 392 million [1] - Major decliners included: - Meidisi (688202) closed at 60.88, down 7.28% with a trading volume of 71,600 shares and a transaction value of 444 million [2] - Meinian Health (002044) closed at 7.26, down 6.08% with a trading volume of 3.7675 million shares and a transaction value of 2.776 billion [2] Capital Flow - The medical services sector saw a net outflow of 1.318 billion from institutional investors, while retail investors had a net inflow of 1.011 billion [2] - The capital flow for specific stocks showed: - Boteng Co. (300363) had a net outflow of 39.83 million from institutional investors [3] - Guangzheng Eye Hospital (002524) had a net inflow of 39.29 million from institutional investors [3] - Lanwei Medical (301060) had a net inflow of 24.71 million from institutional investors [3]

Core Viewpoint - The medical services sector experienced a rise of 1.19% on January 23, with notable gains from companies like Nuohua Zhiyuan, which led the sector's performance [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 4136.16, up 0.33%, while the Shenzhen Component Index closed at 14439.66, up 0.79% [1]. - The medical services sector saw significant individual stock movements, with Nuohua Zhiyuan (688315) closing at 17.00, up 13.26%, and Hai Te Biological (300683) closing at 33.31, up 7.66% [1]. Group 2: Trading Volume and Value - Nuohua Zhiyuan had a trading volume of 219,500 shares and a transaction value of 365 million yuan [1]. - Hai Te Biological recorded a trading volume of 190,900 shares with a transaction value of 632 million yuan [1]. Group 3: Capital Flow - The medical services sector saw a net inflow of 999.1 million yuan from institutional investors, while retail investors experienced a net outflow of 1.069 billion yuan [2]. - The capital flow data indicates that major stocks like Diyan Diagnosis (300244) had a net inflow of 288 million yuan from institutional investors [3].

Group 1 - The core viewpoint of the article highlights the strategic adjustments made by prominent fund managers at E Fund in their investment portfolios for Q4 2025, focusing on sectors like AI, healthcare, consumer goods, and technology [2][4][6][10] Group 2 - Zhang Kun adjusted the structure of investments in the healthcare, consumer, and technology sectors while maintaining a stable position in top holdings, which include Tencent Holdings, Kweichow Moutai, and Alibaba-W [4][5] - Zhang Kun expressed confidence in the improvement of living standards and social security in China over the next decade, suggesting a narrowing gap with developed countries [4] - The AI wave is seen as a significant driver for innovation, with strong domestic demand expected to attract global resources and talent [4][5] Group 3 - Chen Hao focused heavily on AI-related sectors, increasing allocations in power equipment, new energy, non-bank financials, and chemicals, which yielded positive returns [7][8] - Chen Hao anticipates a transition of the AI industry from an acceleration phase in 2025 to a stable growth phase in 2026, emphasizing the importance of structural opportunities and the integration of AI with local applications [7][8] Group 4 - Xiao Nan reduced allocations in high-end and sub-high-end liquor sectors while increasing investments in the livestock industry, anticipating inflation-driven cost increases over the next two years [10] - The top holdings in Xiao Nan's consumer sector fund remained unchanged, including Kweichow Moutai and Midea Group [10]

Core Viewpoint - The National Healthcare Security Administration (NHSA) is promoting the transformation of precision medicine, leading to a strong performance in the medical sector of both A-shares and Hong Kong stocks on January 21 [1][7]. Group 1: Market Performance - In the Hong Kong market, MicroPort Scientific Corporation (MicroPort) surged over 12%, leading the gains, while Alibaba Health increased by over 3% [1][7]. - The Hong Kong medical ETF, Huabao (159137), reached a peak of 1.78% during trading [1][7]. - A-shares also saw a recovery, with Meiyuan Health and Kingmed Diagnostics rising over 3%, and Yuyue Medical and Yingke Medical both increasing over 2% [3][9]. Group 2: ETF Insights - The largest medical ETF in the market (512170) rose over 1.3%, recovering its six-month moving average, with significant capital inflow of over 270 million yuan in net subscriptions [3][9]. - As of January 20, 2026, the medical ETF fund size is 26 billion yuan, making it the largest among medical ETFs in the market [5][11]. Group 3: Policy Developments - The NHSA issued the "Guidelines for the Pricing of Surgical and Treatment Auxiliary Medical Services (Trial)," standardizing pricing for robotic surgeries and remote surgical assistance [5][11]. - The guidelines include 37 pricing items, 5 additional charges, and 1 expansion item, covering various fields such as 3D reconstruction and remote surgery [5][11]. - Notable highlights in pathology services include the establishment of a separate pricing item for pathology diagnosis and the inclusion of digital pathology slice storage in the pricing structure [5][11].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002044 证券简称：美年健康 公告编号：2026-007 美年大健康产业控股股份有限公司关于股东部分股份解除质押及再质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 美年大健康产业控股股份有限公司（以下简称"公司"、"本公司"）于近日收到公司股东上海维途企业发 展中心（有限合伙）（以下简称"上海维途"）的通知，获悉其所持有本公司的部分股份办理了解除质押 及再质押的手续，具体事项如下： ■ 三、股东股份累计质押情况 截至本公告披露日，公司实际控制人俞熔先生及其一致行动人合计持有公司股份681,931,590股，累计质 押股份为515,004,989股，累计质押占其所持股份比例为75.52%。具体情况如下： ■■ 四、其他说明 1.公司股东上海维途本次股份质押融资金额用于其自身生产经营，上海维途资信状况良好，具备相应的 资金偿还能力，还款资金来源为其自有或自筹资金。与公司主营业务、持续经营能力无关，不会对公司 日常经营、公司治理等方面产生不利影响，不涉及业绩补偿义务。 2.实际控制人及其一致 ...

Quantitative Factors and Construction Methods 1. Factor Name: Large Order Transaction Amount Ratio - **Factor Construction Idea**: This factor captures the buying behavior of large funds by analyzing the proportion of large order transaction amounts relative to the total daily transaction amount[7] - **Factor Construction Process**: 1. Use tick-by-tick transaction data to identify buy and sell orders based on bid and ask sequence numbers 2. Filter transactions by order size to identify large orders 3. Calculate the proportion of large buy order transaction amounts to the total daily transaction amount Formula: $ \text{Large Order Transaction Amount Ratio} = \frac{\text{Large Buy Order Transaction Amount}}{\text{Total Daily Transaction Amount}} $ - **Factor Evaluation**: This factor effectively reflects the buying behavior of large funds[7] 2. Factor Name: Net Active Buy Amount Ratio - **Factor Construction Idea**: This factor measures the active buying behavior of investors by calculating the net active buy amount as a proportion of the total daily transaction amount[7] - **Factor Construction Process**: 1. Use tick-by-tick transaction data to classify each transaction as either active buy or active sell based on trade direction 2. Subtract the active sell transaction amount from the active buy transaction amount to obtain the net active buy amount 3. Calculate the proportion of the net active buy amount to the total daily transaction amount Formula: $ \text{Net Active Buy Amount Ratio} = \frac{\text{Active Buy Amount} - \text{Active Sell Amount}}{\text{Total Daily Transaction Amount}} $ - **Factor Evaluation**: This factor provides insights into the active buying behavior of investors[7] --- Factor Backtesting Results 1. Large Order Transaction Amount Ratio - **Top 5 Stocks by 5-Day Average**: 1. 惠博普 (92.6%, 99.6% percentile)[9] 2. 美年健康 (89.6%, 99.2% percentile)[9] 3. 志特新材 (89.2%, 99.2% percentile)[9] 4. 津滨发展 (88.4%, 99.6% percentile)[9] 5. 江南高纤 (87.7%, 98.8% percentile)[9] 2. Net Active Buy Amount Ratio - **Top 5 Stocks by 5-Day Average**: 1. 杭萧钢构 (16.7%, 99.8% percentile)[10] 2. 纬德信息 (15.4%, 100.0% percentile)[10] 3. 中科微至 (15.0%, 99.6% percentile)[10] 4. 新风光 (13.8%, 100.0% percentile)[10] 5. 联合水务 (13.3%, 97.5% percentile)[10] 3. Broad-Based Indices - **Large Order Transaction Amount Ratio (5-Day Average)**: - 上证指数: 73.8% (12.8% percentile)[12] - 上证50: 70.6% (64.2% percentile)[12] - 沪深300: 73.1% (64.2% percentile)[12] - 中证500: 73.0% (6.6% percentile)[12] - 创业板指: 71.6% (90.1% percentile)[12] - **Net Active Buy Amount Ratio (5-Day Average)**: - 上证指数: -5.8% (86.8% percentile)[12] - 上证50: -12.9% (90.5% percentile)[12] - 沪深300: -8.8% (89.3% percentile)[12] - 中证500: -3.4% (86.0% percentile)[12] - 创业板指: -4.4% (84.8% percentile)[12] 4. Industry-Level Results - **Top 5 Industries by Large Order Transaction Amount Ratio (5-Day Average)**: 1. 房地产: 79.8% (90.1% percentile)[13] 2. 煤炭: 78.5% (66.3% percentile)[13] 3. 钢铁: 78.2% (42.8% percentile)[13] 4. 建筑: 77.9% (24.3% percentile)[13] 5. 综合: 77.8% (50.6% percentile)[13] - **Top 5 Industries by Net Active Buy Amount Ratio (5-Day Average)**: 1. 房地产: -9.5% (95.1% percentile)[13] 2. 电子: 2.2% (78.6% percentile)[13] 3. 汽车: 0.9% (60.9% percentile)[13] 4. 家电: 0.1% (84.4% percentile)[13] 5. 通信: -4.7% (89.7% percentile)[13] 5. ETFs - **Top 5 ETFs by Large Order Transaction Amount Ratio (5-Day Average)**: 1. 华泰柏瑞中证A500ETF (92.9%, 96.3% percentile)[15] 2. 易方达中证A500ETF (91.6%, 100.0% percentile)[15] 3. 国泰中证A500ETF (91.5%, 15.6% percentile)[15] 4. 华泰柏瑞沪深300ETF (91.0%, 99.2% percentile)[15] 5. 易方达沪深300ETF (91.0%, 99.6% percentile)[15] - **Top 5 ETFs by Net Active Buy Amount Ratio (5-Day Average)**: 1. 东财上证科创板50成份ETF (23.4%, 100.0% percentile)[16] 2. 海富通上证城投债ETF (20.9%, 88.5% percentile)[16] 3. 国泰上证10年期国债ETF (15.6%, 61.3% percentile)[16] 4. 富国创业板人工智能ETF (14.3%, 65.9% percentile)[16] 5. 嘉实中证稀土产业ETF (14.1%, 92.6% percentile)[16]

证券代码：002044 证券简称：美年健康 公告编号：2026-007 美年大健康产业控股股份有限公司 关于股东部分股份解除质押及再质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 美年大健康产业控股股份有限公司（以下简称"公司"、"本公司"）于近日 收到公司股东上海维途企业发展中心（有限合伙）（以下简称"上海维途"）的 通知，获悉其所持有本公司的部分股份办理了解除质押及再质押的手续，具体 事项如下： 1 公司实际控制人俞熔先生的一致行动人包括：上海天亿资产管理有限公司、上海维途企业发展中心（有 限合伙）、上海美馨投资管理有限公司、上海天亿力升实业控股集团有限公司、世纪长河科技集团有限公 司、上海通怡投资管理有限公司－通怡海川 6 号私募证券投资基金、上海通怡投资管理有限公司－通怡桃 李 3 号私募证券投资基金和上海通怡投资管理有限公司－通怡桃李 12 号私募证券投资基金。 股东名称 是否为实际 控制人及其 一致行动人1 本次解除 质押股数 （股） 占其所 持股份 比例 占公司 总股本 比例 起始日 解除日期 质权人 上海维途 是 16,500,00 ...

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical industry [3] Core Insights - The pharmaceutical and biotechnology index decreased by 0.68% this week, underperforming the CSI 300 index by 0.11 percentage points, ranking 19th in industry performance [12] - The healthcare sector has shown significant growth, with the medical services sub-sector increasing by 16.04% year-to-date, while traditional Chinese medicine has the lowest growth at 1.86% [17][19] - The J.P. Morgan Health Conference highlighted the strategic advancements of top global pharmaceutical companies, with over 20 Chinese firms participating, indicating a trend towards overseas collaboration in innovative drugs [34] Summary by Sections Market Review - The pharmaceutical index has risen by 7.08% from the beginning of 2026 to January 16, outperforming the CSI 300 index by 4.88 percentage points, ranking 8th in industry performance [12] - The medical services sub-sector has the highest year-to-date growth at 16.04%, while the lowest is traditional Chinese medicine at 1.86% [19] Individual Stock Performance - In the A-share market, 206 out of 478 pharmaceutical stocks rose, with the top five performers being Baolait (up 48.76%), Hualan Biological (up 32.72%), and Tianzhihang (up 27.67%) [23] - In the Hong Kong market, 59 out of 116 pharmaceutical stocks increased, with Ark Health leading at 51.66% growth [26] Industry News and Policies - The sixth batch of national high-value medical consumables procurement was opened on January 13, with 202 companies winning bids for 440 products [29] - Medtronic announced a strategic partnership with Precision Neuroscience to develop integrated solutions combining their technologies [29] - Boston Scientific plans to acquire Penumbra for approximately $14.5 billion, enhancing its portfolio in peripheral vascular interventions [30] Weekly Insights - The medical services sector's strong performance is attributed to positive revenue growth, with medical commercial and services sectors showing year-on-year revenue increases of 0.56% and 3.99%, respectively [33] - The J.P. Morgan Health Conference served as a significant platform for discussing trends in drug development and investment strategies, with a focus on AI and international collaborations [34]

Group 1 - The core viewpoint of the news is that Meinian Health has shown significant stock performance with a year-to-date increase of 39.39% and a recent market capitalization of 28.809 billion yuan [1] - As of January 20, the stock price reached 7.36 yuan per share, with a trading volume of 879 million yuan and a turnover rate of 3.13% [1] - The company has experienced net outflows of main funds amounting to 60.0253 million yuan, with large orders showing a buy-sell ratio of 2.06 billion yuan to 2.57 billion yuan [1] Group 2 - Meinian Health operates primarily in health check-ups and management, with 95.67% of its revenue coming from examination services [1] - The company is classified under the pharmaceutical and biological industry, specifically in medical services and hospitals, and is involved in various concept sectors including Alzheimer's, AI applications, and smart healthcare [2] - As of September 30, the company reported a revenue of 6.925 billion yuan for the first nine months of 2025, reflecting a year-on-year decrease of 3.01%, while net profit increased by 110.53% to 51.8599 million yuan [2] Group 3 - Meinian Health has distributed a total of 634 million yuan in dividends since its A-share listing, with 127 million yuan distributed over the past three years [3] - As of September 30, 2025, the number of shareholders decreased by 11.85% to 152,000, while the average circulating shares per person increased by 13.44% to 25,490 shares [2] - The top ten circulating shareholders include notable ETFs, with Huabao Zhongzheng Medical ETF holding 88.664 million shares, a decrease of 15.1218 million shares from the previous period [3]

1月19日，美年健康跌5.09%，截至发稿，报7.27元/股，成交28.40亿元，换手率9.87%，总市值284.57亿 元。 截至发稿，徐治彪累计任职时间10年156天，现任基金资产总规模43.27亿元，任职期间最佳基金回报 201.92%， 任职期间最差基金回报-21.69%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 数据显示，国泰基金旗下1只基金重仓美年健康。国泰大健康股票A（001645）三季度减持147.3万股， 持有股数346.02万股，占基金净值比例为5.36%，位居第九大重仓股。根据测算，今日浮亏损失约 134.95万元。 国泰大健康股票A（001645）成立日期2016年2月3日，最新规模3.03亿。今年以来收益16.32%，同类排 名124/5580；近一年收益21.33%，同类排名3312/4226；成立以来收益190.61%。 国泰大健康股票A（001645）基金经理为徐治彪。 资料显示，美年大健康产业控股股份有限公司位 ...